: Integration of GW has diversified Jazz's neuroscience portfolio, with Epidiolex contributing significantly to its revenue. Current Market Data for Jazz Pharmaceuticals (JAZZ)
: The deal was valued at approximately $7.2 billion .
: This is the current entity that owns all former GWPH assets and continues to develop its pipeline.
Since GW Pharmaceuticals is now part of , investors interested in its cannabinoid platform—including the blockbuster epilepsy drug Epidiolex —must buy shares of the parent company.
Can You Buy GWPH Stock Today? No, you cannot directly purchase stock on the NASDAQ today because GW Pharmaceuticals plc was acquired by Jazz Pharmaceuticals plc in May 2021 .
: GWPH shareholders received $200.00 in cash and $20.00 in Jazz ordinary shares for each GW American Depositary Share (ADS).

